fda nasal spray for depression - Search News

FDA Approves ‘Spravato’ Nasal Spray

Hosted on MSN · 12h

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

Popular Science · 1d

FDA approves first-of-its-kind nasal spray for severe depression

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

Fox Business · 2d

J&J's ketamine-derived nasal spray approved by FDA to treat depression

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.

A Nasal Spray For Depression? FDA Gives Its Approval

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...

ScienceAlert on MSN4h

FDA-Approved Nasal Spray For Depression Is First Of Its Kind

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results